| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| ln Vitro |
Ioxilan, a low-penetration nonionic monomer, enhances the X-ray contrast agent's safety and tolerability. In order to lower osmotic pressure without negatively impacting biological tolerance, a hydrophobic area called a bismethylene group is introduced and covered up with hydrophilic hydroxyl groups, which is how isoxilan developed [1].
|
|---|---|
| ln Vivo |
Dynamic computed tomography can be used in conjunction with a rapid intravenous injection of a water-soluble X-ray contrast agent (Ioxilan) to enhance the detectability of liver lesions. The majority of the water-soluble intravenous X-ray contrast agent that is administered intravenously is dispersed throughout the extracellular fluid and eliminated unaltered by the kidneys. The method of administration, the agent's bloodstream distribution to the area, and the area's final iodine concentration all affect contrast enhancement in a region of interest [1].
|
| ADME/Pharmacokinetics |
Absorption, Distribution and Excretion
Following rapid intravenous injection, peak iodine plasma concentrations are reached immediately. Iodine plasma concentrations decline rapidly within 5 to 10 minutes. This is likely due to dilution of iodine in the intravascular and extravascular fluid compartments. In young, healthy subjects (21–27 years of age), the average amount of iodoxilam excreted unchanged in urine within 24 hours after intravenous injection was 93.7% of the administered dose. These results suggest that bile and/or gastrointestinal excretion is not significant compared to renal excretion. Iodoxilam is primarily distributed in the blood, as evidenced by the apparent volume of distribution (central compartment): 7.2 ± 1.0 L in women and 10.0 ± 2.4 L in men. Total clearance was 95.4 ± 11.1 mL·min⁻¹ in women and 101.0 ± 14.7 mL·min⁻¹ in men, with renal clearance of 89.4 ± 13.3 mL·min⁻¹ and 94.9 ± 16.6 mL·min⁻¹, respectively. Metabolism/MetabolitesNo metabolic evidence was found. Biological Half-LifeThe initial rapid distribution phase had a half-life of 13.1 ± 4.2 min (women) or 23.5 ± 15.3 min (men), followed by elimination phase with half-lives of 102.0 ± 16.9 min (women) and 137 ± 35.4 min (men), respectively. |
| Toxicity/Toxicokinetics |
Effects During Pregnancy and Lactation
◉ Overview of Use During Lactation Very little iodine contrast agents injected intravenously are excreted into breast milk, and their oral absorption rate is also very low. Therefore, they are unlikely to enter the infant's bloodstream and will not cause any adverse effects on breastfed infants. Guidelines developed by multiple professional organizations indicate that breastfeeding mothers do not need to interrupt breastfeeding after receiving iodine-containing contrast agents. However, since there is currently no published experience regarding the use of iodoxilam during lactation, other medications may be preferred, especially when breastfeeding newborns or premature infants. ◉ Effects on Breastfed Infants No published information found as of the revision date. ◉ Effects on Lactation and Breast Milk No published information found as of the revision date. Protein Binding The binding of iodoxilam to plasma proteins is negligible. |
| References |
|
| Additional Infomation |
Iodixaran is an aminobenzoic acid. Iodixaran is a triiodide diagnostic contrast agent. Intravascular injection allows the contrast agent to be visualized along the blood vessels through which it flows, thus enabling radiographic imaging of internal structures before significant blood dilution. Iodixaran is a radiographic contrast agent. Its mechanism of action is as an X-ray contrast agent.
Drug Indications Intra-arterial injection of iodixaran is indicated for the following diagnostic examinations: cerebral angiography (300 mgI/mL), coronary angiography and left ventricular angiography (350 mgI/mL), visceral angiography (350 mgI/mL), aortic angiography (350 mgI/mL), and peripheral angiography (350 mgI/mL). Intravenous injection of iodixaran is indicated for excretory urography and enhanced CT (CECT) imaging of the head and trunk (300 and 350 mgI/mL). FDA Label Mechanism of Action Intravascular injection allows for visualization of blood vessels along the contrast agent's flow path, enabling radiographic imaging of internal structures before significant blood dilution occurs. Pharmacodynamics As with other iodinated contrast agents, the degree of contrast enhancement is directly related to the iodine content in the administered dose. |
| Molecular Formula |
C18H24N3O8I3
|
|---|---|
| Molecular Weight |
791.110460000001
|
| Exact Mass |
790.87
|
| CAS # |
107793-72-6
|
| PubChem CID |
3743
|
| Appearance |
White to off-white solid powder
|
| Density |
2.205 g/cm3
|
| Boiling Point |
827.8ºC at 760 mmHg
|
| Flash Point |
454.4ºC
|
| Vapour Pressure |
4.95E-29mmHg at 25°C
|
| Index of Refraction |
1.721
|
| LogP |
-2.4
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
32
|
| Complexity |
647
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(N(C1=C(I)C(C(NCCO)=O)=C(I)C(C(NCC(O)CO)=O)=C1I)CC(O)CO)=O
|
| InChi Key |
UUMLTINZBQPNGF-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H24I3N3O8/c1-8(28)24(5-10(30)7-27)16-14(20)11(17(31)22-2-3-25)13(19)12(15(16)21)18(32)23-4-9(29)6-26/h9-10,25-27,29-30H,2-7H2,1H3,(H,22,31)(H,23,32)
|
| Chemical Name |
5-[acetyl(2,3-dihydroxypropyl)amino]-3-N-(2,3-dihydroxypropyl)-1-N-(2-hydroxyethyl)-2,4,6-triiodobenzene-1,3-dicarboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 250 mg/mL (~316.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.63 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.63 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (2.63 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2640 mL | 6.3202 mL | 12.6405 mL | |
| 5 mM | 0.2528 mL | 1.2640 mL | 2.5281 mL | |
| 10 mM | 0.1264 mL | 0.6320 mL | 1.2640 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
